INS and diabetes mellitus: In our population of patients with type 2 diabetes on insulin, GLP-1 RAs appear to have similar efficacy in terms of A1C reduction and discontinuation of prandial insulin regardless of baseline BMI, duration of diabetes, or baseline total daily insulin dose when analyzed with specific cutoffs in these categories.